{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:42:08Z","timestamp":1792636928581,"version":"4.5.0"},"reference-count":34,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blood tests for Alzheimer's disease (AD) are emerging as alternative to amyloid positron emission tomography (PET) scans and analysis of cerebrospinal fluid (CSF). However, their effect on clinical decision-making and subsequent wait times in the diagnostic process remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate wait times in the diagnostic process to determine potential eligibility for amyloid-targeting treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a structured expert consultation process to elicit how a blood test to rule out or to confirm AD pathology would inform decisions in primary and secondary care and a Markov model to project how those decisions would affect wait times for specialist visits and amyloid PET scans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with referral decisions based on the results of a brief cognitive assessment, the addition of an AD blood test is projected to reduce wait times for subsequent specialist appointments by 35%. A blood test for confirmation of AD pathology would also eliminate wait times for amyloid PET scans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High-performing AD blood tests have the potential to streamline the diagnostic journey and reduce wait times<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877261467345","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:29:56Z","timestamp":1784208596000},"page":"177-185","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Projected effect of a high performing blood test on wait times for determination of Alzheimer's disease pathology in the United States"],"prefix":"10.1177","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4666-9132","authenticated-orcid":false,"given":"Soeren","family":"Mattke","sequence":"first","affiliation":[{"name":"The USC Brain Health Observatory, USC Dornsife, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4119-4265","authenticated-orcid":false,"given":"Jiahe","family":"Chen","sequence":"additional","affiliation":[{"name":"The USC Brain Health Observatory, USC Dornsife, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9484-5295","authenticated-orcid":false,"given":"Mark","family":"Hanson","sequence":"additional","affiliation":[{"name":"The USC Brain Health Observatory, USC Dornsife, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8793-2489","authenticated-orcid":false,"given":"Kim G.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Leahy","sequence":"additional","affiliation":[{"name":"Memorial Healthcare Institute for Neuroscience, Owosso, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2181-3839","authenticated-orcid":false,"given":"David A.","family":"Merrill","sequence":"additional","affiliation":[{"name":"Pacific Neuroscience Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Shada","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-8502","authenticated-orcid":false,"given":"Jorge G.","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Memorial Healthcare System"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0312-4"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.7249\/RR2272"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.7249\/RR2503"},{"key":"e_1_3_3_8_2","unstructured":"Penn Memory Center. Patient Care https:\/\/pennmemorycenter.org\/patient-care\/ (2023 accessed 7 November 2023)."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70054"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01272-z"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119011071.iemp0137"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13764"},{"key":"e_1_3_3_15_2","article-title":"Blood-based biomarkers for Alzheimer\u2019s pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times","volume":"12","author":"Mattke S","year":"2020","unstructured":"Mattke S, Cho SK, Bittner T, et al. Blood-based biomarkers for Alzheimer\u2019s pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times. Alzheimers Dement (Amst) 2020; 12: e12081.","journal-title":"Alzheimers Dement (Amst)"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12470"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2019.01.004"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004826"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.3543"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12822"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12694"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318294b1cf"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.001"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/208642"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-6-1"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1287\/mnsc.9.3.458"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15020167"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.13855"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330619"},{"key":"e_1_3_3_30_2","article-title":"Usage patterns of cognitive assessments during Medicare's Annual Wellness Visit: a national survey","volume":"21","author":"Liu Y","year":"2025","unstructured":"Liu Y, Ozawa T, Mattke S. Usage patterns of cognitive assessments during Medicare's Annual Wellness Visit: a national survey. Alzheimers Dement 2025; 21: e14539.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_3_31_2","article-title":"Prevalence and predictors of diagnosed mild cognitive impairment among Medicare beneficiaries","volume":"18","author":"Couch E","year":"2026","unstructured":"Couch E, Ugoh M, Thomas L, et al. Prevalence and predictors of diagnosed mild cognitive impairment among Medicare beneficiaries. Alzheimers Dement (Amst) 2026; 18: e70212.","journal-title":"Alzheimers Dement (Amst)"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70966"},{"key":"e_1_3_3_33_2","article-title":"The Lecanemab Clarity AD open-label extension in early Alzheimer\u2019s disease: initial findings from the 48-month analysis","volume":"21","author":"van Dyck CH","year":"2025","unstructured":"van Dyck CH, Li D, Kanekiyo M, et al. The Lecanemab Clarity AD open-label extension in early Alzheimer\u2019s disease: initial findings from the 48-month analysis. Alzheimers Dement 2025; 21: e108905.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_3_34_2","article-title":"Alzheimer\u2019s disease drug development pipeline: 2025","volume":"11","author":"Cummings JL","year":"2025","unstructured":"Cummings JL, Zhou Y, Lee G, et al. Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimers Dement (N Y) 2025; 11: e70098.","journal-title":"Alzheimers Dement (N Y)"},{"key":"e_1_3_3_35_2","article-title":"Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings","volume":"21","author":"Palmqvist S","year":"2025","unstructured":"Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings. Alzheimers Dement 2025; 21: e70535.","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877261467345","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877261467345","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877261467345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:07:45Z","timestamp":1788253665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877261467345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/13872877261467345"],"URL":"https:\/\/doi.org\/10.1177\/13872877261467345","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}